Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piracetam for cognitive impairment in elderly patients with major depressive disorder
IRCT20250929067414N3Phase 3Recruiting
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Piracetam add-on with Placebo add-on (2 arms). Primary endpoint: Mean total NUCOG score. Started Feb 2026; status: recruiting.
02
Drugs
piracetam
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20250929067414N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250929067414N3.